$ACRS
Aclaris Therapeutics, Inc. Stock $acrs

$acrs Overview Financials Valuation SEC Filings Company Website

2019 Q4 Form 10-K Financial Statement

#000155837021001717 Filed on February 25, 2021

Income Statement

Concept	2019 Q4	2018	2017 Q4
Revenue	$1.100M	$6.151M	$1.000M
YoY Change	-37.85%	266.13%
Cost Of Revenue	$1.030M	$4.329M	$750.0K
YoY Change	-18.9%	257.77%
Gross Profit	$70.00K	$1.822M	$250.0K
YoY Change	-86.27%	279.58%
Gross Profit Margin	6.36%	29.62%	25.0%
Selling, General & Admin	$6.060M	$25.76M	$12.50M
YoY Change	16.76%	-22.2%	167.09%
% of Gross Profit	8657.14%	1413.83%	5000.0%
Research & Development	$11.57M	$60.84M	$13.19M
YoY Change	-40.24%	52.91%	90.06%
% of Gross Profit	16528.57%	3339.24%	5276.0%
Depreciation & Amortization	$320.0K	$1.879M	$180.0K
YoY Change	-66.67%	369.75%	350.0%
% of Gross Profit	457.14%	103.13%	72.0%
Operating Expenses	$17.62M	$60.84M	$25.69M
YoY Change	-28.23%	-16.54%	120.89%
Operating Profit	-$17.55M	-$84.78M	-$25.44M
YoY Change	-27.0%	17.07%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net	-$1.900M	$2.676M	$680.0K
YoY Change	-487.76%	29.28%	353.33%
Pretax Income	-$19.45M	-$82.10M	-$24.76M
YoY Change	-17.44%	16.71%	115.68%
Income Tax	$0.00	$0.00	$10.00K
% Of Pretax Income
Net Earnings	-$18.59M	-$132.7M	-$22.93M
YoY Change	-51.78%	93.72%	99.74%
Net Earnings / Revenue	-1690.0%	-2157.99%	-2293.0%
Basic Earnings Per Share
Diluted Earnings Per Share	-$448.9K	-$4.033M	-$742.8K
COMMON SHARES
Basic Shares Outstanding
Diluted Shares Outstanding

Balance Sheet

Concept	2019 Q4	2018	2017 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$73.27M	$168.0M	$193.9M
YoY Change	-56.39%	-13.36%	41.33%
Cash & Equivalents	$34.19M	$57.00M	$20.20M
Short-Term Investments	$39.08M	$111.0M	$173.7M
Other Short-Term Assets	$8.100M	$11.00M	$5.900M
YoY Change	-26.36%	86.44%	353.85%
Inventory	$0.00	$0.00
Prepaid Expenses
Receivables	$704.0K	$600.0K	$500.0K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$83.80M	$179.5M	$200.2M
YoY Change	-53.31%	-10.34%	44.44%
LONG-TERM ASSETS
Property, Plant & Equipment	$2.470M	$2.300M	$2.200M
YoY Change	7.39%	4.55%	340.0%
Goodwill
YoY Change
Intangibles	$7.199M
YoY Change
Long-Term Investments			$15.00M
YoY Change			-59.35%
Other Assets	$4.825M	$68.00M	$300.0K
YoY Change	-92.9%	22566.67%	200.0%
Total Long-Term Assets	$14.49M	$96.10M	$43.30M
YoY Change	-84.92%	121.94%	15.47%
TOTAL ASSETS
Total Short-Term Assets	$83.80M	$179.5M	$200.2M
Total Long-Term Assets	$14.49M	$96.10M	$43.30M
Total Assets	$98.30M	$275.6M	$243.5M
YoY Change	-64.33%	13.18%	38.27%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$9.917M	$14.80M	$7.800M
YoY Change	-32.99%	89.74%	178.57%
Accrued Expenses	$7.721M	$6.100M	$3.000M
YoY Change	26.57%	103.33%	66.67%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$100.0K	$100.0K	$100.0K
YoY Change	0.0%	0.0%
Total Short-Term Liabilities	$22.43M	$27.30M	$12.80M
YoY Change	-17.83%	113.28%	106.45%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$29.90M	$0.00
YoY Change	-100.0%
Other Long-Term Liabilities	$3.736M	$2.600M	$4.900M
YoY Change	43.69%	-46.94%	1125.0%
Total Long-Term Liabilities	$3.736M	$32.50M	$4.900M
YoY Change	-88.5%	563.27%	1125.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$22.43M	$27.30M	$12.80M
Total Long-Term Liabilities	$3.736M	$32.50M	$4.900M
Total Liabilities	$28.39M	$60.40M	$18.20M
YoY Change	-53.0%	231.87%	175.76%
SHAREHOLDERS EQUITY
Retained Earnings	-$453.5M
YoY Change
Common Stock	$0.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$69.91M	$215.1M	$225.3M
YoY Change
Total Liabilities & Shareholders Equity	$98.30M	$275.6M	$243.5M
YoY Change	-64.33%	13.18%	38.27%

Cashflow Statement

Concept	2019 Q4	2018	2017 Q4
OPERATING ACTIVITIES
Net Income	-$18.59M	-$132.7M	-$22.93M
YoY Change	-51.78%	93.72%	99.74%
Depreciation, Depletion And Amortization	$320.0K	$1.879M	$180.0K
YoY Change	-66.67%	369.75%	350.0%
Cash From Operating Activities	-$20.39M	-$100.8M	-$18.21M
YoY Change	-25.17%	84.43%	125.65%
INVESTING ACTIVITIES
Capital Expenditures	-$260.0K	$1.356M	-$580.0K
YoY Change	73.33%	-209.35%	866.67%
Acquisitions
YoY Change
Other Investing Activities	$56.70M	$10.72M	-$20.99M
YoY Change	-180.59%	-119.68%	-73.01%
Cash From Investing Activities	$56.44M	$9.367M	-$21.56M
YoY Change	-180.06%	-116.82%	-72.3%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-30.01M	128.3M	-70.00K
YoY Change	-123.41%	27.76%	-100.07%
NET CHANGE
Cash From Operating Activities	-20.39M	-100.8M	-18.21M
Cash From Investing Activities	56.44M	9.367M	-21.56M
Cash From Financing Activities	-30.01M	128.3M	-70.00K
Net Change In Cash	6.040M	36.82M	-39.84M
YoY Change	-80.15%	-469.65%	-421.81%
FREE CASH FLOW
Cash From Operating Activities	-$20.39M	-$100.8M	-$18.21M
Capital Expenditures	-$260.0K	$1.356M	-$580.0K
Free Cash Flow	-$20.13M	-$102.2M	-$17.63M
YoY Change	-25.72%	91.25%	120.1%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2019Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2020Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2019Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2020Q4	us-gaap	Common Stock Value CommonStockValue
CY2019Q4	us-gaap	Common Stock Value CommonStockValue
CY2020	dei	Entity Central Index Key EntityCentralIndexKey	0001557746
CY2020	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2020	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2020
CY2020	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2020	dei	Amendment Flag AmendmentFlag	false
CY2020	dei	Document Annual Report DocumentAnnualReport	true
CY2020	dei	Document Transition Report DocumentTransitionReport	false
CY2019Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2020Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2019Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	41485638
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	45109314
CY2019Q4	us-gaap	Fair Value Assets Level2 To Level1 Transfers Amount FairValueAssetsLevel2ToLevel1TransfersAmount	0
CY2020Q4	us-gaap	Fair Value Assets Level2 To Level1 Transfers Amount FairValueAssetsLevel2ToLevel1TransfersAmount	0
CY2019	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Net FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet	0
CY2020	dei	Entity Registrant Name EntityRegistrantName	Aclaris Therapeutics, Inc.
CY2020	dei	Entity Small Business EntitySmallBusiness	true
CY2020Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	us-gaap:OtherLiabilitiesCurrent
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	us-gaap:OtherLiabilitiesNoncurrent
CY2020	us-gaap	Revenue Practical Expedient Incremental Cost Of Obtaining Contract RevenuePracticalExpedientIncrementalCostOfObtainingContract	true
CY2020	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Net FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet	0
CY2018	us-gaap	Federal Income Tax Expense Benefit Continuing Operations FederalIncomeTaxExpenseBenefitContinuingOperations	0
CY2019	us-gaap	Federal Income Tax Expense Benefit Continuing Operations FederalIncomeTaxExpenseBenefitContinuingOperations	0
CY2020	us-gaap	Federal Income Tax Expense Benefit Continuing Operations FederalIncomeTaxExpenseBenefitContinuingOperations	0
CY2018	us-gaap	State And Local Income Tax Expense Benefit Continuing Operations StateAndLocalIncomeTaxExpenseBenefitContinuingOperations	0
CY2019	us-gaap	State And Local Income Tax Expense Benefit Continuing Operations StateAndLocalIncomeTaxExpenseBenefitContinuingOperations	0
CY2020	us-gaap	State And Local Income Tax Expense Benefit Continuing Operations StateAndLocalIncomeTaxExpenseBenefitContinuingOperations	0
CY2019Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	us-gaap:OtherLiabilitiesCurrent
CY2019Q4	us-gaap	Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	us-gaap:OtherLiabilitiesNoncurrent
CY2020Q4	us-gaap	Operating Lease Liability Statement Of Financial Position Extensible List OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList	us-gaap:OperatingLeaseLiability
CY2020	dei	Document Type DocumentType	10-K
CY2020	dei	Document Period End Date DocumentPeriodEndDate	2020-12-31
CY2020	dei	Entity File Number EntityFileNumber	001-37581
CY2020	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2020	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	46-0571712
CY2020	dei	Entity Address Address Line1 EntityAddressAddressLine1	640 Lee Road, Suite 200
CY2020	dei	Entity Address City Or Town EntityAddressCityOrTown	Wayne
CY2020	dei	Entity Address State Or Province EntityAddressStateOrProvince	PA
CY2020	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	19087
CY2020	dei	City Area Code CityAreaCode	484
CY2020	dei	Local Phone Number LocalPhoneNumber	324-7933
CY2020	dei	Security12b Title Security12bTitle	Common Stock, $0.00001 par value
CY2020	dei	Trading Symbol TradingSymbol	ACRS
CY2020	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2020	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	Yes
CY2020	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2020	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2020	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2020	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2020	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2020	acrs	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2020	dei	Entity Shell Company EntityShellCompany	false
CY2020Q2	dei	Entity Public Float EntityPublicFloat	65500000
CY2021Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	51804258
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	22063000
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	34187000
CY2019Q4	us-gaap	Restricted Cash RestrictedCash	1750000
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	32068000
CY2019Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	39078000
CY2020Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	772000
CY2019Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	704000
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2590000
CY2019Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	7199000
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	4514000
CY2019Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3118000
CY2019Q4	us-gaap	Assets Of Disposal Group Including Discontinued Operation Current AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent	4966000
CY2020Q4	us-gaap	Assets Current AssetsCurrent	57493000
CY2019Q4	us-gaap	Assets Current AssetsCurrent	83803000
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1654000
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2470000
CY2020Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	7123000
CY2019Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	4825000
CY2020Q4	us-gaap	Assets Assets	70784000
CY2019Q4	us-gaap	Assets Assets	98297000
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	5254000
CY2019Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	9917000
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	5906000
CY2019Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	7721000
CY2020Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	603000
CY2019Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	637000
CY2020Q4	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation Current LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent	3111000
CY2019Q4	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation Current LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent	4157000
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	14874000
CY2019Q4	us-gaap	Liabilities Current LiabilitiesCurrent	22432000
CY2020Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	3179000
CY2019Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	3736000
CY2020Q4	us-gaap	Long Term Debt LongTermDebt	10653000
CY2020Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	4061000
CY2019Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	1668000
CY2020Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	367000
CY2019Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	549000
CY2020Q4	us-gaap	Liabilities Liabilities	33134000
CY2019Q4	us-gaap	Liabilities Liabilities	28385000
CY2019Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.00001
CY2020Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.00001
CY2019Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000
CY2020Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000
CY2019Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2020Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2019Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2019Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	45109314
CY2019Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	41485638
CY2020Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	542286000
CY2019Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	523505000
CY2020Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-94000
CY2019Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-66000
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-504542000
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-453527000
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	37650000
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	69912000
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	70784000
CY2019Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	98297000
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	6482000
CY2019	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	4227000
CY2018	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	6151000
CY2020	us-gaap	Cost Of Revenue CostOfRevenue	5133000
CY2019	us-gaap	Cost Of Revenue CostOfRevenue	4055000
CY2018	us-gaap	Cost Of Revenue CostOfRevenue	4329000
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	31731000
CY2019	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	64899000
CY2018	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	60841000
CY2020	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	20530000
CY2019	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	27827000
CY2018	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	25761000
CY2019	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	18504000
CY2020	us-gaap	Costs And Expenses CostsAndExpenses	57394000
CY2019	us-gaap	Costs And Expenses CostsAndExpenses	115285000
CY2018	us-gaap	Costs And Expenses CostsAndExpenses	90931000
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-50912000
CY2019	us-gaap	Operating Income Loss OperatingIncomeLoss	-111058000
CY2018	us-gaap	Operating Income Loss OperatingIncomeLoss	-84780000
CY2020	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-424000
CY2019	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-2484000
CY2018	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	2676000
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-51336000
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-113542000
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-82104000
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-182000
CY2020	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-51154000
CY2019	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-113542000
CY2018	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-82104000
CY2020	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	139000
CY2019	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	-47812000
CY2018	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	-50634000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-51015000
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-161354000
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-132738000
CY2020	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.20
CY2019	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-3.90
CY2018	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-4.03
CY2020	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	42539293
CY2019	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	41323921
CY2018	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	32909762
CY2018	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	0
CY2019	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	0
CY2020	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	0
CY2020	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-2000
CY2019	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	28000
CY2018	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	145000
CY2020	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-26000
CY2019	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-25000
CY2018	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	32000
CY2020	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-28000
CY2019	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	3000
CY2018	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	177000
CY2020	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-51043000
CY2019	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-161351000
CY2018	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-132561000
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	225262000
CY2018	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	2215000
CY2018	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	-52000
CY2018	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	145000
CY2018	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	32000
CY2018	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	20055000
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-132738000
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	215124000
CY2019	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	-38000
CY2019	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	28000
CY2019	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-25000
CY2019	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	16177000
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-161354000
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	69912000
CY2020	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	-669000
CY2020	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	378000
CY2020	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-2000
CY2020	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-26000
CY2020	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	11207000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-51015000
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	37650000
CY2020	us-gaap	Profit Loss ProfitLoss	-51015000
CY2019	us-gaap	Profit Loss ProfitLoss	-161354000
CY2018	us-gaap	Profit Loss ProfitLoss	-132738000
CY2020	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1324000
CY2019	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	6409000
CY2018	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1879000
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	11207000
CY2019	us-gaap	Share Based Compensation ShareBasedCompensation	16177000
CY2018	us-gaap	Share Based Compensation ShareBasedCompensation	20055000
CY2020	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	2393000
CY2019	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	734000
CY2018	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	1272000
CY2019	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	18504000
CY2019	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	27638000
CY2018	acrs	Payment Of Development Milestone Operating PaymentOfDevelopmentMilestoneOperating	717000
CY2019	acrs	Gain Of Sale Of Product Under Collaborative Arrangement GainOfSaleOfProductUnderCollaborativeArrangement	1850000
CY2020	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	-182000
CY2020	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-4898000
CY2019	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	809000
CY2018	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	4380000
CY2020	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-1689000
CY2019	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-3233000
CY2018	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-62000
CY2020	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-5219000
CY2019	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-3160000
CY2018	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	6964000
CY2020	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-3728000
CY2019	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-1967000
CY2018	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	6792000
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-38633000
CY2019	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-96445000
CY2018	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-100811000
CY2020	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	453000
CY2019	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1613000
CY2018	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1356000
CY2018	acrs	Payments To Acquire Product Under Collaborative Arrangement PaymentsToAcquireProductUnderCollaborativeArrangement	67122000
CY2019	acrs	Receipts From Disposition Of Product Under Collaborative Arrangement ReceiptsFromDispositionOfProductUnderCollaborativeArrangement	34186000
CY2020	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	47714000
CY2019	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	137385000
CY2018	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	161598000
CY2020	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	54554000
CY2019	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	210491000
CY2018	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	239443000
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	6387000
CY2019	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	105679000
CY2018	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	9367000
CY2020	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	10913000
CY2018	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	29910000
CY2019	us-gaap	Proceeds From Repayments Of Secured Debt ProceedsFromRepaymentsOfSecuredDebt	-30000000
CY2018	acrs	Payment Of Development Milestone Financing PaymentOfDevelopmentMilestoneFinancing	1783000
CY2020	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	137000
CY2019	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	523000
CY2018	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	648000
CY2020	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	211000
CY2020	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	70000
CY2019	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	207000
CY2018	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	577000
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	18372000
CY2019	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-30316000
CY2018	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	128261000
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-13874000
CY2019	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-21082000
CY2018	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	36817000
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	35937000
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	57019000
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	20202000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	22063000
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	35937000
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	57019000
CY2019	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	124000
CY2020	us-gaap	Nature Of Operations NatureOfOperations	<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">1. Organization and Nature of Business</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><b style="font-weight:bold;">Overview</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Aclaris Therapeutics, Inc. was incorporated under the laws of the State of Delaware in 2012. In July 2015, Aclaris Therapeutics International Limited (“ATIL”) was established under the laws of the United Kingdom as a wholly-owned subsidiary of Aclaris Therapeutics, Inc. In March 2016, Vixen Pharmaceuticals, Inc. (“Vixen”) became a wholly-owned subsidiary of Aclaris Therapeutics, Inc., and in September 2018, Vixen was dissolved. In August 2017, Confluence Life Sciences, Inc. (now known as Aclaris Life Sciences, Inc.) (“Confluence”) was acquired by Aclaris Therapeutics, Inc. and became a wholly-owned subsidiary thereof. Aclaris Therapeutics, Inc., ATIL, Vixen and Confluence are referred to collectively as the “Company.” The Company is a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases. In addition to developing its novel drug candidates, the Company is pursuing strategic alternatives, including identifying and consummating transactions with third-party partners, to further develop, obtain marketing approval for and/or commercialize its novel drug candidates. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-family:'Calibri Light';visibility:hidden;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><b style="font-weight:bold;">Liquidity</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company’s consolidated financial statements have been prepared on the basis of continuity of operations, realization of assets and the satisfaction of liabilities in the ordinary course of business. As of December 31, 2020, the Company had cash, cash equivalents and marketable securities of $54.1 million and an accumulated deficit of $504.5 million. Since inception, the Company has incurred net losses and negative cash flows from its operations. Prior to the acquisition of Confluence in August 2017, the Company had never generated revenue. There can be no assurance that profitable operations will ever be achieved, and, if achieved, will be sustained on a continuing basis. In addition, development activities, including clinical and preclinical testing of the Company’s drug candidates, will require significant additional financing. The future viability of the Company is dependent on its ability to successfully develop its drug candidates and to generate revenue from identifying and consummating transactions with third-party partners to further develop, obtain marketing approval for and/or commercialize its development assets or to raise additional capital to finance its operations. The Company will require additional capital to complete the clinical development of ATI-450 and ATI-1777, to develop its preclinical compounds, and to support its discovery efforts. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company has taken a number of actions to support its operations and meet its liquidity needs. In September 2019, the Company announced the completion of a strategic review and its decision to refocus its resources on its immuno-inflammatory development programs and to actively seek partners for its drug candidates and commercial products. As a result of this decision, the Company restructured its operations and reduced its workforce, which lowered operating costs. In October 2019, the Company sold the worldwide rights to RHOFADE (oxymetazoline hydrochloride) cream, 1% (“RHOFADE”) to further its focus on its development programs and improve cash flow. In March 2020, the Company borrowed $11.0 million under a term loan facility with Silicon Valley Bank. In August 2020, the Company <span style="background-color:#ffffff;">entered into an equity purchase agreement (the “Purchase Agreement”) with Lincoln Park Capital Fund, LLC (“Lincoln Park”). </span>As of December 31, 2020, the Company had sold 2,111,170 shares of common stock to Lincoln Park under the Purchase Agreement for net proceeds of $7.7 million. The Company did not sell any additional shares prior to terminating the Purchase Agreement in January 2021 in connection with a public offering of common stock in which it sold 6,306,271 shares of its common stock for net proceeds of $103.5 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company’s plans to further address its liquidity needs primarily include its ability to control the timing and spending on its research and development programs. The Company may also consider other plans to fund its operations including: (1) raising additional capital through debt or equity financings; (2) identifying third-party partners to further develop, obtain marketing approval for and/or commercialize its drug candidates, which may generate revenue and/or milestone payments; (3) reducing spending on one or more research and development programs by delaying or discontinuing development; and/or (4) further restructuring its operations to change its overhead structure.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Additional funds may not be available on a timely basis, on commercially acceptable terms, or at all, and such funds, if raised, may not be sufficient to enable the Company to continue to implement its long-term business strategy. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Company’s ability to raise additional capital may be adversely impacted by potential worsening global economic conditions and the recent disruptions to, and volatility in, the credit and financial markets in the United States and worldwide resulting from the ongoing COVID-19 pandemic. If the Company is unable to raise sufficient additional capital or generate revenue from transactions with potential third-party partners for the development and/or commercialization of its drug candidates, it may need to substantially curtail planned operations. The Company’s failure to raise capital as and when needed could have a negative impact on its financial condition and ability to pursue its business strategies. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"/>In accordance with Accounting Standards Update (“ASU”) 2014-15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern (Subtopic 205-40), the Company evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that its consolidated financial statements are issued. As of the report date, the Company does not believe that substantial doubt exists about its ability to continue as a going concern. The Company believes its existing cash, cash equivalents and marketable securities are sufficient to fund its operating and capital expenditure requirements for a period greater than 12 months from the date of issuance of these consolidated financial statements. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;"></span></p>
CY2020Q4	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	54100000
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-504500000
CY2018	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	161000
CY2020	acrs	Fair Value Of Warrants Issued In Connection With Debt Financing FairValueOfWarrantsIssuedInConnectionWithDebtFinancing	378000
CY2018	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	2131000
CY2018	acrs	Stock Issued In Settlement Of Development Milestone StockIssuedInSettlementOfDevelopmentMilestone	2215000
CY2018	acrs	Deferred Offering Costs Incurred But Not Yet Paid DeferredOfferingCostsIncurredButNotYetPaid	210000
CY2019	acrs	Operating Lease Asset Recorded As Result Of New Accounting Standard OperatingLeaseAssetRecordedAsResultOfNewAccountingStandard	2132000
CY2020	us-gaap	Stock Issued1 StockIssued1	263000
CY2020	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><b style="font-weight:bold;">Reclassifications</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;">Certain prior year amounts have been reclassified to conform to the current year financial statement presentation.</p>
CY2019Q3	us-gaap	Restructuring And Related Cost Number Of Positions Eliminated RestructuringAndRelatedCostNumberOfPositionsEliminated	86
CY2020	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><b style="font-weight:bold;">Use of Estimates</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these financial statements include, but are not limited to, research and development expenses, contingent consideration and the valuation of stock-based awards. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. The COVID-19 pandemic has resulted in a global slowdown in economic activity. As of the date of issuance of these financial statements, the Company is not aware of any specific event or circumstance that would require an update to its estimates, assumptions and judgments or revise the carrying value of its assets or liabilities. Actual results could differ from the Company’s estimates.</p>
CY2020	us-gaap	Revenue Practical Expedient Financing Component RevenuePracticalExpedientFinancingComponent	false
CY2019	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	18500000
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2019Q4	us-gaap	Fair Value Assets Level1 To Level2 Transfers Amount FairValueAssetsLevel1ToLevel2TransfersAmount	0
CY2020Q4	us-gaap	Fair Value Assets Level1 To Level2 Transfers Amount FairValueAssetsLevel1ToLevel2TransfersAmount	0
CY2020Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	32066000
CY2020Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	2000
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	32068000
CY2019Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	39074000
CY2019Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	7000
CY2019Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	3000
CY2019Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	39078000
CY2020	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><b style="font-weight:bold;">Concentration of Credit Risk and of Significant Suppliers</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash, cash equivalents and marketable securities. The Company holds all cash, cash equivalents and marketable securities balances at one accredited financial institution, in amounts that exceed federally insured limits. The Company does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company is dependent on third-party manufacturers to supply drug product, including all underlying components, for its research and development activities, including preclinical and clinical testing. These activities could be adversely affected by a significant interruption in the supply of active pharmaceutical ingredients or other components. </p>
CY2020	acrs	Concentration Of Credit Risk Number Of Financial Institutions ConcentrationOfCreditRiskNumberOfFinancialInstitutions	1
CY2020	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	2
CY2019Q4	acrs	Percentage Of Payments Received In Connection With License Or Sublicense Of Assets Transferred PercentageOfPaymentsReceivedInConnectionWithLicenseOrSublicenseOfAssetsTransferred	0.25
CY2019Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	435000
CY2020Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	4277000
CY2019Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	4536000
CY2020Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2623000
CY2019Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2066000
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1654000
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2470000
CY2020	us-gaap	Depreciation Depreciation	1100000
CY2019	us-gaap	Depreciation Depreciation	1500000
CY2018	us-gaap	Depreciation Depreciation	1200000
CY2020Q4	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	7380000
CY2019Q4	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	7380000
CY2020Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	257000
CY2019Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	181000
CY2018	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	75000
CY2019	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	75000
CY2020	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	75000
CY2020Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	75000
CY2020Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	75000
CY2020Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	75000
CY2020Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	75000
CY2020Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	75000
CY2020Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	119000
CY2020Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	494000
CY2020Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	3971000
CY2019Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	3321000
CY2020Q4	acrs	Accrued Research And Development Costs Current AccruedResearchAndDevelopmentCostsCurrent	761000
CY2019Q4	acrs	Accrued Research And Development Costs Current AccruedResearchAndDevelopmentCostsCurrent	2857000
CY2020Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1174000
CY2019Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1543000
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	5906000
CY2019Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	7721000
CY2019Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000
CY2020Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000
CY2019Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2020Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2019Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000
CY2019Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2020	acrs	Common Stock Number Of Votes Per Share CommonStockNumberOfVotesPerShare	1
CY2020	us-gaap	Dividends Common Stock DividendsCommonStock	0
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0087
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0227
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0266
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y1M6D
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y2M12D
CY2018	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y3M18D
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.8519
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.9936
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.9678
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3328757
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	20.69
CY2017	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y3M18D
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	19812000
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1459800
CY2018	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	20.97
CY2018	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	59450
CY2018	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	9.70
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	724000
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	447026
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	24.62
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	4282081
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	20.53
CY2018	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y10M24D
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	2404000
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	44500
CY2019	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	5.75
CY2019	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	142779
CY2019	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	1.33
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	112000
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	1081581
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	23.01
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3102221
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	20.33
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y7M6D
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	148000
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	734800
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	1.30
CY2020	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	53737
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	1.30
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	145000
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	911786
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	22.41
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2871498
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	15.16
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y9M18D
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	4890000
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	2871498
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	15.16
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P6Y9M18D
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	4890000
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	1844197
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	18.92
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P5Y9M18D
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	1424000
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.93
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	4.63
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	16.55
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	11207000
CY2019	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	16082000
CY2018	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	16563000
CY2020Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	4200000
CY2020Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Share Based Awards Other Than Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions	5500000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-51015000
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-161354000
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-132738000
CY2020	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	42539293
CY2019	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	41323921
CY2018	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	32909762
CY2020Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	3497000
CY2019Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	4074000
CY2020	acrs	Number Of Financing Lease Arrangements NumberOfFinancingLeaseArrangements	2
CY2019	acrs	Finance Lease Term FinanceLeaseTerm	P4Y
CY2020	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.20
CY2019	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-3.90
CY2018	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-4.03
CY2020	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5575906
CY2019	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	6695136
CY2018	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4908488
CY2019	us-gaap	Gain Loss On Termination Of Lease GainLossOnTerminationOfLease	200000
CY2020	us-gaap	Operating Lease Cost OperatingLeaseCost	1013000
CY2019	us-gaap	Operating Lease Cost OperatingLeaseCost	808000
CY2020	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	113000
CY2019	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	443000
CY2020	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	5000
CY2019	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	87000
CY2020	us-gaap	Lease Cost LeaseCost	118000
CY2019	us-gaap	Lease Cost LeaseCost	530000
CY2020	us-gaap	Operating Lease Expense OperatingLeaseExpense	1000000.0
CY2019	us-gaap	Operating Lease Expense OperatingLeaseExpense	1000000.0
CY2018	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	900000
CY2020Q4	us-gaap	Net Rentable Area NetRentableArea	33019
CY2020	acrs	Area Of Property Sub Subleased AreaOfPropertySubSubleased	8115
CY2019Q1	us-gaap	Net Rentable Area NetRentableArea	20433
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	603000
CY2019Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	526000
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2894000
CY2019Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	3548000
CY2020	us-gaap	Operating Lease Payments OperatingLeasePayments	907000
CY2019	us-gaap	Operating Lease Payments OperatingLeasePayments	755000
CY2020	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	5000
CY2019	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	87000
CY2020	acrs	Finance Lease Principal Payments Other FinanceLeasePrincipalPaymentsOther	137000
CY2019	acrs	Finance Lease Principal Payments Other FinanceLeasePrincipalPaymentsOther	523000
CY2019Q4	acrs	Lease Liabilities New Operating Leases LeaseLiabilitiesNewOperatingLeases	3060000
CY2020Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P6Y
CY2019Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P6Y9M18D
CY2019Q4	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P0Y10M24D
CY2020Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.101
CY2019Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.101
CY2020Q4	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.100
CY2019Q4	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.100
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	924000
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	949000
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	866000
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	343000
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	352000
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	1301000
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	4735000
CY2020Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	1238000
CY2020Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	3497000
CY2020Q4	acrs	Deferred Tax Assets Capitalized Start Up Costs DeferredTaxAssetsCapitalizedStartUpCosts	6509000
CY2019Q4	acrs	Deferred Tax Assets Capitalized Start Up Costs DeferredTaxAssetsCapitalizedStartUpCosts	6904000
CY2020Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	8732000
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-51215000
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-161192000
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-132473000
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	18000
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-162000
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-265000
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-51197000
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-161354000
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-132738000
CY2020	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2019	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2018	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2020	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.075
CY2019	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.066
CY2018	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.035
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.026
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.015
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.021
CY2020	acrs	Effective Income Tax Rate Reconciliation Permanent Differences EffectiveIncomeTaxRateReconciliationPermanentDifferences	-0.026
CY2019	acrs	Effective Income Tax Rate Reconciliation Permanent Differences EffectiveIncomeTaxRateReconciliationPermanentDifferences	-0.030
CY2018	acrs	Effective Income Tax Rate Reconciliation Permanent Differences EffectiveIncomeTaxRateReconciliationPermanentDifferences	-0.008
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.281
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.262
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.257
CY2019Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	7417000
CY2020Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	4611000
CY2019Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	4456000
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	14526000
CY2019Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	12973000
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	745000
CY2020	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.004
CY2019	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.001
CY2018	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.001
CY2020Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	101277000
CY2019Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	90298000
CY2019Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	588000
CY2020Q4	acrs	Deferred Tax Assets Lease Liabilities DeferredTaxAssetsLeaseLiabilities	888000
CY2019Q4	acrs	Deferred Tax Assets Lease Liabilities DeferredTaxAssetsLeaseLiabilities	945000
CY2020Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	602000
CY2019Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	618000
CY2020Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	137890000
CY2019Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	124199000
CY2020Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	209000
CY2019Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	206000
CY2020Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	2033000
CY2019Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	1741000
CY2020Q4	acrs	Deferred Tax Liabilities Right To Use Assets DeferredTaxLiabilitiesRightToUseAssets	1026000
CY2019Q4	acrs	Deferred Tax Liabilities Right To Use Assets DeferredTaxLiabilitiesRightToUseAssets	1235000
CY2020Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	430000
CY2019Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	600000
CY2020Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	3698000
CY2019Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	3782000
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	134559000
CY2019Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	120966000
CY2020Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	367000
CY2019Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	549000
CY2019Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	120966000
CY2018Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	80985000
CY2017Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	46878000
CY2020	acrs	Valuation Allowance Deferred Tax Asset Decrease Recorded ValuationAllowanceDeferredTaxAssetDecreaseRecorded	-58000
CY2020	acrs	Valuation Allowance Deferred Tax Asset Increase In Amount ValuationAllowanceDeferredTaxAssetIncreaseInAmount	13651000
CY2019	acrs	Valuation Allowance Deferred Tax Asset Increase In Amount ValuationAllowanceDeferredTaxAssetIncreaseInAmount	39981000
CY2018	acrs	Valuation Allowance Deferred Tax Asset Increase In Amount ValuationAllowanceDeferredTaxAssetIncreaseInAmount	34107000
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	134559000
CY2019Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	120966000
CY2018Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	80985000
CY2020	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent Of Match DefinedContributionPlanEmployerMatchingContributionPercentOfMatch	1
CY2020	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent DefinedContributionPlanEmployerMatchingContributionPercent	0.04
CY2020	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	400000
CY2019	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	700000
CY2018	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	700000
CY2020	us-gaap	Severance Costs1 SeveranceCosts1	100000
CY2020	us-gaap	Payments For Restructuring PaymentsForRestructuring	300000
CY2019	us-gaap	Severance Costs1 SeveranceCosts1	2700000
CY2019	us-gaap	Payments For Restructuring PaymentsForRestructuring	2300000
CY2020	us-gaap	Disposal Group Including Discontinued Operation Revenue DisposalGroupIncludingDiscontinuedOperationRevenue	424000
CY2019	us-gaap	Disposal Group Including Discontinued Operation Revenue DisposalGroupIncludingDiscontinuedOperationRevenue	13896000
CY2018	us-gaap	Disposal Group Including Discontinued Operation Revenue DisposalGroupIncludingDiscontinuedOperationRevenue	3940000
CY2019	us-gaap	Disposal Group Including Discontinued Operation Costs Of Goods Sold DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold	4522000
CY2018	us-gaap	Disposal Group Including Discontinued Operation Costs Of Goods Sold DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold	1969000
CY2020	acrs	Disposal Group Including Discontinued Operation Research And Development Expense DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense	1000
CY2019	acrs	Disposal Group Including Discontinued Operation Research And Development Expense DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense	503000
CY2018	acrs	Disposal Group Including Discontinued Operation Research And Development Expense DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense	2168000
CY2020	acrs	Disposal Group Including Discontinued Operation Sales And Marketing Expense DisposalGroupIncludingDiscontinuedOperationSalesAndMarketingExpense	283000
CY2019	acrs	Disposal Group Including Discontinued Operation Sales And Marketing Expense DisposalGroupIncludingDiscontinuedOperationSalesAndMarketingExpense	23112000
CY2018	acrs	Disposal Group Including Discontinued Operation Sales And Marketing Expense DisposalGroupIncludingDiscontinuedOperationSalesAndMarketingExpense	47827000
CY2020	us-gaap	Disposal Group Including Discontinued Operation General And Administrative Expense DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense	1000
CY2019	us-gaap	Disposal Group Including Discontinued Operation General And Administrative Expense DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense	2929000
CY2018	us-gaap	Disposal Group Including Discontinued Operation General And Administrative Expense DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense	2058000
CY2019	acrs	Disposal Group Including Discontinued Operation Impairment Of Intangible Assets DisposalGroupIncludingDiscontinuedOperationImpairmentOfIntangibleAssets	27638000
CY2019	us-gaap	Disposal Group Including Discontinued Operation Depreciation And Amortization DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization	4426000
CY2018	us-gaap	Disposal Group Including Discontinued Operation Depreciation And Amortization DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization	552000
CY2020	us-gaap	Disposal Group Including Discontinued Operation Operating Expense DisposalGroupIncludingDiscontinuedOperationOperatingExpense	285000
CY2019	us-gaap	Disposal Group Including Discontinued Operation Operating Expense DisposalGroupIncludingDiscontinuedOperationOperatingExpense	63130000
CY2018	us-gaap	Disposal Group Including Discontinued Operation Operating Expense DisposalGroupIncludingDiscontinuedOperationOperatingExpense	54574000
CY2020	us-gaap	Disposal Group Including Discontinued Operation Operating Income Loss DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss	139000
CY2019	us-gaap	Disposal Group Including Discontinued Operation Operating Income Loss DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss	-49234000
CY2018	us-gaap	Disposal Group Including Discontinued Operation Operating Income Loss DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss	-50634000
CY2019	us-gaap	Disposal Group Including Discontinued Operation Other Income DisposalGroupIncludingDiscontinuedOperationOtherIncome	1422000
CY2020	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Before Income Tax DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax	139000
CY2019	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Before Income Tax DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax	-47812000
CY2018	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Before Income Tax DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax	-50634000
CY2020	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	139000
CY2019	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	-47812000
CY2018	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	-50634000
CY2020	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic And Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare	0.00
CY2019	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic And Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare	-1.16
CY2018	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic And Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare	-1.54
CY2020	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	42539293
CY2019	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	41323921
CY2018	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	32909762
CY2020	us-gaap	Disposal Group Including Discontinued Operation Revenue DisposalGroupIncludingDiscontinuedOperationRevenue	424000
CY2019	us-gaap	Disposal Group Including Discontinued Operation Revenue DisposalGroupIncludingDiscontinuedOperationRevenue	13896000
CY2018	us-gaap	Disposal Group Including Discontinued Operation Revenue DisposalGroupIncludingDiscontinuedOperationRevenue	3940000
CY2019Q4	us-gaap	Disposal Group Including Discontinued Operation Accounts Notes And Loans Receivable Net DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet	4966000
CY2019Q4	us-gaap	Assets Of Disposal Group Including Discontinued Operation Current AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent	4966000
CY2020Q4	us-gaap	Disposal Group Including Discontinued Operation Accounts Payable Current DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent	1175000
CY2019Q4	us-gaap	Disposal Group Including Discontinued Operation Accounts Payable Current DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent	1705000
CY2020Q4	us-gaap	Disposal Group Including Discontinued Operation Accrued Liabilities Current DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent	1936000
CY2019Q4	us-gaap	Disposal Group Including Discontinued Operation Accrued Liabilities Current DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent	2452000
CY2020Q4	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation Current LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent	3111000
CY2019Q4	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation Current LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent	4157000
CY2019Q4	us-gaap	Disposal Group Including Discontinued Operation Accounts Notes And Loans Receivable Net DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet	5000000.0
CY2019	us-gaap	Depreciation And Amortization Discontinued Operations DepreciationAndAmortizationDiscontinuedOperations	313000
CY2019	acrs	Stock Based Compensation Expense Discontinued Operations StockBasedCompensationExpenseDiscontinuedOperations	95000
CY2019	acrs	Intangible Assets Impairment Charge Discontinued Operations IntangibleAssetsImpairmentChargeDiscontinuedOperations	27638000
CY2019	acrs	Gain Loss On Disposal Of Property And Equipment Discontinued Operations GainLossOnDisposalOfPropertyAndEquipmentDiscontinuedOperations	-248000
CY2019	acrs	Noncash Income Expense Before Sale Of Business NoncashIncomeExpenseBeforeSaleOfBusiness	28294000
CY2019	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations	26624000
CY2019	us-gaap	Gain Loss On Termination Of Lease GainLossOnTerminationOfLease	200000
CY2020	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	2
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	6482000
CY2020	us-gaap	Cost Of Revenue CostOfRevenue	5133000
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	31731000
CY2020	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	20530000
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-50912000
CY2020	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Before Income Tax DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax	139000
CY2019	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	4227000
CY2019	us-gaap	Cost Of Revenue CostOfRevenue	4055000
CY2019	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	64899000
CY2019	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	27827000
CY2019	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	18504000
CY2019	us-gaap	Operating Income Loss OperatingIncomeLoss	-111058000
CY2019	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Before Income Tax DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax	-47812000
CY2018	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	6151000
CY2018	us-gaap	Cost Of Revenue CostOfRevenue	4329000
CY2018	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	60841000
CY2018	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	25761000
CY2018	us-gaap	Operating Income Loss OperatingIncomeLoss	-84780000
CY2018	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Before Income Tax DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax	-50634000

Files In Submission

Name	View Source	Status
0001558370-21-001717-index-headers.html	Edgar Link	pending
0001558370-21-001717-index.html	Edgar Link	pending
0001558370-21-001717.txt	Edgar Link	pending
0001558370-21-001717-xbrl.zip	Edgar Link	pending
acrs-20201231.xsd	Edgar Link	pending
acrs-20201231x10k.htm	Edgar Link	pending
acrs-20201231x10k_htm.xml	Edgar Link	completed
acrs-20201231xex10d12.htm	Edgar Link	pending
acrs-20201231xex10d16.htm	Edgar Link	pending
acrs-20201231xex21d1.htm	Edgar Link	pending
acrs-20201231xex23d1.htm	Edgar Link	pending
acrs-20201231xex31d1.htm	Edgar Link	pending
acrs-20201231xex31d2.htm	Edgar Link	pending
acrs-20201231xex32d1.htm	Edgar Link	pending
acrs-20201231xex4d2.htm	Edgar Link	pending
acrs-20201231_cal.xml	Edgar Link	unprocessable
acrs-20201231_def.xml	Edgar Link	unprocessable
acrs-20201231_lab.xml	Edgar Link	unprocessable
acrs-20201231_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ACRS
Aclaris Therapeutics, Inc. Stock $acrs

2019 Q4 Form 10-K Financial Statement

#000155837021001717 Filed on February 25, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ACRS Aclaris Therapeutics, Inc. Stock $acrs

2019 Q4 Form 10-K Financial Statement

#000155837021001717 Filed on February 25, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ACRS
Aclaris Therapeutics, Inc. Stock $acrs